Eintrag weiter verarbeiten
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , |
| In: | Clinical Cancer Research, 14, 2008, 23, S. 7838-7842 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas |
|---|---|
| author |
Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas |
| spellingShingle |
Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas Clinical Cancer Research Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients Cancer Research Oncology |
| author_sort |
fleischmann, achim |
| spelling |
Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-08-1432 <jats:title>Abstract</jats:title> <jats:p>Purpose: Neutral endopeptidase (CD10), an ectopeptidase bound to the cell surface, is thought to be a potential prognostic marker for prostate cancer.</jats:p> <jats:p>Experimental Design: Prostate cancer patients (N = 3,261) treated by radical prostatectomy at a single institution were evaluated by using tissue microarray. Follow-up data were available for 2,385 patients. The cellular domain (membranous, membranous-cytoplasmatic, and cytoplasmatic only) of CD10 expression was analyzed immunohistochemically and correlated with various clinical and histopathologic features of the tumors.</jats:p> <jats:p>Results: CD10 expression was detected in 62.2% of cancer samples and occurred preferentially in higher Gleason pattern (P &lt; 0.0001). CD10 expression positively correlated with adverse tumor features such as elevated preoperative prostate-specific antigen (PSA), higher Gleason score, and advanced stage (P &lt; 0.0001 each). Survival analyses showed that PSA recurrence was significantly associated with the staining pattern of CD10 expression. Outcome significantly declined from negative over membranous, membranous-cytoplasmatic, to exclusively cytoplasmatic CD10 expression (P &lt; 0.0001). In multivariate analysis, CD10 expression was an independent predictor for PSA failure (P = 0.0343).</jats:p> <jats:p>Conclusions: CD10 expression is an unfavorable independent risk factor in prostate cancer. The subcellular location of CD10 protein is associated with specific clinical courses, suggesting an effect on different important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies.</jats:p> Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-08-1432 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA4LTE0MzI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA4LTE0MzI |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2008 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2008 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
fleischmann2008distinctsubcellularexpressionpatternsofneutralendopeptidasecd10inprostatecancerpredictdivergingclinicalcoursesinsurgicallytreatedpatients |
| publishDateSort |
2008 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_unstemmed |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_full |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_fullStr |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_full_unstemmed |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_short |
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_sort |
distinct subcellular expression patterns of neutral endopeptidase (cd10) in prostate cancer predict diverging clinical courses in surgically treated patients |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-08-1432 |
| publishDate |
2008 |
| physical |
7838-7842 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Purpose: Neutral endopeptidase (CD10), an ectopeptidase bound to the cell surface, is thought to be a potential prognostic marker for prostate cancer.</jats:p>
<jats:p>Experimental Design: Prostate cancer patients (N = 3,261) treated by radical prostatectomy at a single institution were evaluated by using tissue microarray. Follow-up data were available for 2,385 patients. The cellular domain (membranous, membranous-cytoplasmatic, and cytoplasmatic only) of CD10 expression was analyzed immunohistochemically and correlated with various clinical and histopathologic features of the tumors.</jats:p>
<jats:p>Results: CD10 expression was detected in 62.2% of cancer samples and occurred preferentially in higher Gleason pattern (P &lt; 0.0001). CD10 expression positively correlated with adverse tumor features such as elevated preoperative prostate-specific antigen (PSA), higher Gleason score, and advanced stage (P &lt; 0.0001 each). Survival analyses showed that PSA recurrence was significantly associated with the staining pattern of CD10 expression. Outcome significantly declined from negative over membranous, membranous-cytoplasmatic, to exclusively cytoplasmatic CD10 expression (P &lt; 0.0001). In multivariate analysis, CD10 expression was an independent predictor for PSA failure (P = 0.0343).</jats:p>
<jats:p>Conclusions: CD10 expression is an unfavorable independent risk factor in prostate cancer. The subcellular location of CD10 protein is associated with specific clinical courses, suggesting an effect on different important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies.</jats:p> |
| container_issue |
23 |
| container_start_page |
7838 |
| container_title |
Clinical Cancer Research |
| container_volume |
14 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341182221647874 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:15:39.715Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Distinct+Subcellular+Expression+Patterns+of+Neutral+Endopeptidase+%28CD10%29+in+Prostate+Cancer+Predict+Diverging+Clinical+Courses+in+Surgically+Treated+Patients&rft.date=2008-12-01&genre=article&issn=1557-3265&volume=14&issue=23&spage=7838&epage=7842&pages=7838-7842&jtitle=Clinical+Cancer+Research&atitle=Distinct+Subcellular+Expression+Patterns+of+Neutral+Endopeptidase+%28CD10%29+in+Prostate+Cancer+Predict+Diverging+Clinical+Courses+in+Surgically+Treated+Patients&aulast=Erbersdobler&aufirst=Andreas&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-08-1432&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341182221647874 |
| author | Fleischmann, Achim, Schlomm, Thorsten, Huland, Hartwig, Köllermann, Jens, Simon, Philipp, Mirlacher, Martina, Salomon, Georg, Chun, Felix H.K., Steuber, Thomas, Simon, Ronald, Sauter, Guido, Graefen, Markus, Erbersdobler, Andreas |
| author_facet | Fleischmann, Achim, Schlomm, Thorsten, Huland, Hartwig, Köllermann, Jens, Simon, Philipp, Mirlacher, Martina, Salomon, Georg, Chun, Felix H.K., Steuber, Thomas, Simon, Ronald, Sauter, Guido, Graefen, Markus, Erbersdobler, Andreas, Fleischmann, Achim, Schlomm, Thorsten, Huland, Hartwig, Köllermann, Jens, Simon, Philipp, Mirlacher, Martina, Salomon, Georg, Chun, Felix H.K., Steuber, Thomas, Simon, Ronald, Sauter, Guido, Graefen, Markus, Erbersdobler, Andreas |
| author_sort | fleischmann, achim |
| container_issue | 23 |
| container_start_page | 7838 |
| container_title | Clinical Cancer Research |
| container_volume | 14 |
| description | <jats:title>Abstract</jats:title> <jats:p>Purpose: Neutral endopeptidase (CD10), an ectopeptidase bound to the cell surface, is thought to be a potential prognostic marker for prostate cancer.</jats:p> <jats:p>Experimental Design: Prostate cancer patients (N = 3,261) treated by radical prostatectomy at a single institution were evaluated by using tissue microarray. Follow-up data were available for 2,385 patients. The cellular domain (membranous, membranous-cytoplasmatic, and cytoplasmatic only) of CD10 expression was analyzed immunohistochemically and correlated with various clinical and histopathologic features of the tumors.</jats:p> <jats:p>Results: CD10 expression was detected in 62.2% of cancer samples and occurred preferentially in higher Gleason pattern (P &lt; 0.0001). CD10 expression positively correlated with adverse tumor features such as elevated preoperative prostate-specific antigen (PSA), higher Gleason score, and advanced stage (P &lt; 0.0001 each). Survival analyses showed that PSA recurrence was significantly associated with the staining pattern of CD10 expression. Outcome significantly declined from negative over membranous, membranous-cytoplasmatic, to exclusively cytoplasmatic CD10 expression (P &lt; 0.0001). In multivariate analysis, CD10 expression was an independent predictor for PSA failure (P = 0.0343).</jats:p> <jats:p>Conclusions: CD10 expression is an unfavorable independent risk factor in prostate cancer. The subcellular location of CD10 protein is associated with specific clinical courses, suggesting an effect on different important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-08-1432 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA4LTE0MzI |
| imprint | American Association for Cancer Research (AACR), 2008 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2008 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T16:15:39.715Z |
| match_str | fleischmann2008distinctsubcellularexpressionpatternsofneutralendopeptidasecd10inprostatecancerpredictdivergingclinicalcoursesinsurgicallytreatedpatients |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 7838-7842 |
| publishDate | 2008 |
| publishDateSort | 2008 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Fleischmann, Achim Schlomm, Thorsten Huland, Hartwig Köllermann, Jens Simon, Philipp Mirlacher, Martina Salomon, Georg Chun, Felix H.K. Steuber, Thomas Simon, Ronald Sauter, Guido Graefen, Markus Erbersdobler, Andreas 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-08-1432 <jats:title>Abstract</jats:title> <jats:p>Purpose: Neutral endopeptidase (CD10), an ectopeptidase bound to the cell surface, is thought to be a potential prognostic marker for prostate cancer.</jats:p> <jats:p>Experimental Design: Prostate cancer patients (N = 3,261) treated by radical prostatectomy at a single institution were evaluated by using tissue microarray. Follow-up data were available for 2,385 patients. The cellular domain (membranous, membranous-cytoplasmatic, and cytoplasmatic only) of CD10 expression was analyzed immunohistochemically and correlated with various clinical and histopathologic features of the tumors.</jats:p> <jats:p>Results: CD10 expression was detected in 62.2% of cancer samples and occurred preferentially in higher Gleason pattern (P &lt; 0.0001). CD10 expression positively correlated with adverse tumor features such as elevated preoperative prostate-specific antigen (PSA), higher Gleason score, and advanced stage (P &lt; 0.0001 each). Survival analyses showed that PSA recurrence was significantly associated with the staining pattern of CD10 expression. Outcome significantly declined from negative over membranous, membranous-cytoplasmatic, to exclusively cytoplasmatic CD10 expression (P &lt; 0.0001). In multivariate analysis, CD10 expression was an independent predictor for PSA failure (P = 0.0343).</jats:p> <jats:p>Conclusions: CD10 expression is an unfavorable independent risk factor in prostate cancer. The subcellular location of CD10 protein is associated with specific clinical courses, suggesting an effect on different important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies.</jats:p> Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients Clinical Cancer Research |
| spellingShingle | Fleischmann, Achim, Schlomm, Thorsten, Huland, Hartwig, Köllermann, Jens, Simon, Philipp, Mirlacher, Martina, Salomon, Georg, Chun, Felix H.K., Steuber, Thomas, Simon, Ronald, Sauter, Guido, Graefen, Markus, Erbersdobler, Andreas, Clinical Cancer Research, Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients, Cancer Research, Oncology |
| title | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_full | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_fullStr | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_full_unstemmed | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_short | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| title_sort | distinct subcellular expression patterns of neutral endopeptidase (cd10) in prostate cancer predict diverging clinical courses in surgically treated patients |
| title_unstemmed | Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-08-1432 |